IOVANCE BIOTHERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$28.06 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-07
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$28.06M, a 118.50% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $1.41M.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$165.28M, a 436.65% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$51.06M, a 810.62% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$63.22M, a 263.55% decline from fiscal 2017.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $38.66M, a 47.14% decline from fiscal 2016.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $73.13M.
- IOVANCE BIOTHERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$11.32M, a 144.86% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 45 month | Cash and Cash Equivalents, Period Increase (Decrease) 48 month | Cash and Cash Equivalents, Period Increase (Decrease) 51 month | Cash and Cash Equivalents, Period Increase (Decrease) 54 month | Cash and Cash Equivalents, Period Increase (Decrease) 57 month | Cash and Cash Equivalents, Period Increase (Decrease) 60 month | Cash and Cash Equivalents, Period Increase (Decrease) 66 month | Cash and Cash Equivalents, Period Increase (Decrease) 69 month | Cash and Cash Equivalents, Period Increase (Decrease) 72 month | Cash and Cash Equivalents, Period Increase (Decrease) 78 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | -$28.06M 10-Q · filed 2019-05-07 | -$26.64M derived: sum of 2 quarters · filed 2019-05-07 | -$191.92M derived: sum of 3 quarters · filed 2019-05-07 | -$242.99M derived: sum of 4 quarters · filed 2019-05-07 | ||||||||||||||
| 2018-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$163.87M derived: sum of 2 quarters · filed 2019-02-28 | -$214.93M derived: sum of 3 quarters · filed 2019-02-28 | -$63.22M 10-K · filed 2019-02-28 | ||||||||||||||
| 2018-09-30 | -$165.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$216.34M derived: sum of 2 quarters · filed 2018-11-06 | -$64.64M 10-Q · filed 2018-11-06 | -$82.64M derived: sum of 4 quarters · filed 2019-05-07 | ||||||||||||||
| 2018-06-30 | -$51.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $100.64M 10-Q · filed 2018-08-07 | $82.64M derived: sum of 3 quarters · filed 2019-05-07 | $131.73M derived: sum of 4 quarters · filed 2019-05-07 | ||||||||||||||
| 2018-03-31 | $151.71M 10-Q · filed 2019-05-07 | $133.70M derived: sum of 2 quarters · filed 2019-05-07 | $182.80M derived: sum of 3 quarters · filed 2019-05-07 | $189.98M derived: sum of 4 quarters · filed 2019-05-07 | ||||||||||||||
| 2017-12-31 | -$18.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $31.09M derived: sum of 2 quarters · filed 2019-02-28 | $38.27M derived: sum of 3 quarters · filed 2019-02-28 | $38.66M 10-K · filed 2019-02-28 | ||||||||||||||
| 2017-09-30 | $49.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $56.28M derived: sum of 2 quarters · filed 2018-11-06 | $56.66M 10-Q · filed 2018-11-06 | $70.48M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||||
| 2017-06-30 | $7.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $7.57M 10-Q · filed 2018-08-07 | $21.39M derived: sum of 3 quarters · filed 2019-02-28 | -$6.68M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||||
| 2017-03-31 | $382.00K 10-Q · filed 2018-05-10 | $14.20M derived: sum of 2 quarters · filed 2019-02-28 | -$13.87M derived: sum of 3 quarters · filed 2019-02-28 | $68.18M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||||
| 2016-12-31 | $13.82M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$14.25M derived: sum of 2 quarters · filed 2019-02-28 | $67.80M derived: sum of 3 quarters · filed 2019-02-28 | $73.13M 10-K · filed 2019-02-28 | ||||||||||||||
| 2016-09-30 | -$28.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $53.98M derived: sum of 2 quarters · filed 2017-11-02 | $59.31M 10-Q · filed 2017-11-02 | $62.12M derived: sum of 4 quarters · filed 2018-03-12 | ||||||||||||||
| 2016-06-30 | $82.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $87.38M 10-Q · filed 2017-08-03 | $87.58M 10-Q · filed 2016-08-09 | $90.19M derived: sum of 3 quarters · filed 2018-03-12 | $108.41M derived: sum of 4 quarters · filed 2018-03-12 | |||||||||||||
| 2016-03-31 | $5.33M 10-Q · filed 2017-05-03 | -$4.70M 10-Q · filed 2016-05-09 | $8.14M derived: sum of 2 quarters · filed 2018-03-12 | $26.36M derived: sum of 3 quarters · filed 2018-03-12 | -$72.36M derived: sum of 4 quarters · filed 2018-03-12 | |||||||||||||
| 2015-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $21.03M derived: sum of 2 quarters · filed 2018-03-12 | -$77.69M derived: sum of 3 quarters · filed 2018-03-12 | -$11.32M 10-K · filed 2018-03-12 | -$31.27M 10-K · filed 2016-03-11 | |||||||||||||
| 2015-09-30 | $18.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$80.51M derived: sum of 2 quarters · filed 2016-11-04 | -$14.14M 10-Q · filed 2016-11-04 | -$34.70M 10-Q · filed 2015-11-06 | $13.58M derived: sum of 4 quarters · filed 2017-03-09 | |||||||||||||
| 2015-06-30 | -$98.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$32.35M 10-Q · filed 2016-08-09 | -$32.35M 10-Q · filed 2015-08-10 | -$4.63M derived: sum of 3 quarters · filed 2017-03-09 | -$5.88M derived: sum of 4 quarters · filed 2017-03-09 | |||||||||||||
| 2015-03-31 | $66.37M 10-Q · filed 2016-05-09 | $66.37M 10-Q · filed 2015-05-11 | $94.09M derived: sum of 2 quarters · filed 2017-03-09 | $92.84M derived: sum of 3 quarters · filed 2017-03-09 | $93.34M derived: sum of 4 quarters · filed 2017-03-09 | |||||||||||||
| 2014-12-31 | $27.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $26.47M derived: sum of 2 quarters · filed 2017-03-09 | $26.97M derived: sum of 3 quarters · filed 2017-03-09 | $25.24M 10-K · filed 2017-03-09 | $25.24M 10-K · filed 2015-03-16 | |||||||||||||
| 2014-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$754.70K derived: sum of 2 quarters · filed 2015-11-06 | -$2.48M 10-Q · filed 2015-11-06 | -$2.48M 10-Q · filed 2014-11-13 | $17.06M derived: sum of 4 quarters · filed 2016-03-11 | |||||||||||||
| 2014-06-30 | $496.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$1.23M 10-Q · filed 2015-08-10 | $18.31M derived: sum of 3 quarters · filed 2016-03-11 | $17.87M derived: sum of 4 quarters · filed 2016-03-11 | ||||||||||||||
| 2014-03-31 | -$1.73M 10-Q · filed 2015-05-11 | $17.81M derived: sum of 2 quarters · filed 2016-03-11 | $17.37M derived: sum of 3 quarters · filed 2016-03-11 | $17.94M derived: sum of 4 quarters · filed 2016-03-11 | $17.94M 10-Q · filed 2014-05-14 | |||||||||||||
| 2013-12-31 | $19.54M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $19.10M derived: sum of 2 quarters · filed 2016-03-11 | $19.67M derived: sum of 3 quarters · filed 2016-03-11 | $19.67M 10-K · filed 2016-03-11 | $19.67M 10-K · filed 2014-03-28 | $19.67M 10-K · filed 2014-03-28 | ||||||||||||
| 2013-09-30 | -$439.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $129.80K derived: sum of 2 quarters · filed 2014-11-13 | $129.80K 10-Q · filed 2014-11-13 | $129.80K derived: sum of 4 quarters · filed 2014-11-13 | $129.80K 10-Q · filed 2013-11-14 | |||||||||||||
| 2013-06-30 | $569.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $569.58K 10-Q · filed 2014-08-08 | $569.58K 10-Q · filed 2013-10-23 | $569.58K derived: sum of 3 quarters · filed 2014-08-08 | $553.84K derived: sum of 4 quarters · filed 2014-08-08 | $569.58K 10-Q · filed 2013-10-23 | ||||||||||||
| 2013-03-31 | $0.00 10-Q · filed 2013-10-23 | $0.00 derived: sum of 2 quarters · filed 2014-03-28 | -$15.74K derived: sum of 3 quarters · filed 2014-03-28 | $0.00 derived: sum of 4 quarters · filed 2014-03-28 | $0.00 10-Q · filed 2013-10-23 | |||||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | -$15.74K derived: sum of 2 quarters · filed 2014-03-28 | $0.00 derived: sum of 3 quarters · filed 2014-03-28 | -$510.22K 10-K · filed 2014-03-28 | ||||||||||||||
| 2012-09-30 | -$15.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $0.00 derived: sum of 2 quarters · filed 2013-11-14 | -$510.22K 10-Q · filed 2013-11-14 | -$910.61K derived: sum of 4 quarters · filed 2013-11-14 | $0.00 10-Q · filed 2013-01-25 | |||||||||||||
| 2012-06-30 | $15.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-23 | -$494.48K 10-Q · filed 2013-10-23 | -$894.87K derived: sum of 3 quarters · filed 2013-10-23 | -$252.82K derived: sum of 4 quarters · filed 2013-10-23 | $15.74K 10-Q/A · filed 2012-09-10 | |||||||||||||
| 2012-03-31 | -$510.22K 10-Q · filed 2013-10-23 | -$910.61K derived: sum of 2 quarters · filed 2013-10-23 | -$268.56K derived: sum of 3 quarters · filed 2013-10-23 | -$722.99K derived: sum of 4 quarters · filed 2013-10-23 | $0.00 10-Q · filed 2012-05-15 | |||||||||||||
| 2011-12-31 | -$400.39K derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-23 | $241.65K derived: sum of 2 quarters · filed 2013-09-23 | -$212.78K derived: sum of 3 quarters · filed 2013-09-23 | -$782.25K 10-K · filed 2013-09-23 | $510.22K 10-K · filed 2012-03-30 | |||||||||||||
| 2011-09-30 | $642.04K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-01-25 | $187.61K derived: sum of 2 quarters · filed 2013-01-25 | -$381.86K 10-Q · filed 2013-01-25 | $114.67K derived: sum of 4 quarters · filed 2013-01-25 | $910.61K 10-Q · filed 2011-11-21 | |||||||||||||
| 2011-06-30 | -$454.43K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-09-10 | -$1.02M 10-Q/A · filed 2012-09-10 | -$1.02M 10-Q/A · filed 2011-09-01 | -$527.38K derived: sum of 3 quarters · filed 2012-09-10 | $59.30K derived: sum of 4 quarters · filed 2012-09-10 | $268.56K 10-Q/A · filed 2011-09-01 | ||||||||||||
| 2011-03-31 | -$569.48K 10-Q · filed 2012-05-15 | -$72.95K derived: sum of 2 quarters · filed 2012-05-15 | $513.73K derived: sum of 3 quarters · filed 2012-05-15 | |||||||||||||||
| 2010-12-31 | $496.53K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $1.08M derived: sum of 2 quarters · filed 2012-03-30 | $1.28M 10-K · filed 2012-03-30 | |||||||||||||||
| 2010-09-30 | $586.68K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-21 | $787.69K 10-Q · filed 2011-11-21 | ||||||||||||||||
| 2010-06-30 | $201.01K 10-Q/A · filed 2011-09-01 | |||||||||||||||||
| 2009-12-31 | $5.35K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |